Year archive

Theranexus — 2024 filings

All 30 regulatory filings released by Theranexus (ALTHX) in 2024, sourced directly from the official regulator.

30 Filings

2024 Period

2024 filings (30)

Filing	Released	Lang
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON Capital/Financing Update	2024-12-17	English
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANCEMENT Capital/Financing Update	2024-12-17	French
THERANEXUS ET EXELTIS (INSUD PHARMA) ANNONCENT UN ACCORD DE LICENCE POUR LA COMMERCIALISATION DU TX01 DE THERANEXUS DANS LE TRAITEMENT DE DEUX MALADIES NEUROLOGIQUES RARES Capital/Financing Update	2024-12-17	French
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS Capital/Financing Update	2024-12-17	English
Update on the Theranexus' Batten-1 project in CLN3 Batten's disease Earnings Release FY 2024	2024-11-19	English
Theranexus fait le point sur son programme Batten-1 dans la maladie de Batten CLN3 Investor Presentation	2024-11-19	French
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024 Earnings Release 9M 2024	2024-10-23	English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2024 Earnings Release 9M 2024	2024-10-23	French
THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE Regulatory Filings	2024-10-17	English
THERANEXUS S'ASSOCIE À SYNERLAB POUR PRÉPARER LA COMMERCIALISATION DE SA FORMULATION PÉDIATRIQUE DANS LA MALADIE DE NIEMANN-PICK DE TYPE C Regulatory Filings	2024-10-17	French
Rapport semestriel 1er semestre 2024 Interim / Quarterly Report H1 2024	2024-09-26	French
THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS Earnings Release H1 2024	2024-09-26	English
THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2024 Earnings Release H1 2024	2024-09-26	French
Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1 Share Issue/Capital Change	2024-07-11	English
Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avancement de Batten-1 Share Issue/Capital Change	2024-07-11	French
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE '2024 RESEARCH PACT' PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION Regulatory Filings	2024-07-03	English
THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET ' PACTE DE RECHERCHE 2024 ' DE LA REGION AUVERGNE-RHÔNE-ALPES Regulatory Filings	2024-07-03	French
Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death Regulatory Filings	2024-06-06	English
Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale Earnings Release FY 2024	2024-06-06	French
MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023 Report Publication Announcement	2024-05-02	French
URD 2023 Annual Report FY 2022	2024-04-30	French
THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT Earnings Release FY 2023	2024-04-29	English
THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS Earnings Release FY 2023	2024-04-29	French
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital Declaration of Voting Results & Voting Rights Announcements	2024-04-26	French
Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the 'Innovations in biotherapies and biomanufacturing' call for proposals from France 2030 to develop a novel antisense oligon Regulatory Filings	2024-04-23	English
Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets ' Innovations en Biothérapies et Bioproduction ' de France 2030, pour développ Capital/Financing Update	2024-04-23	French
Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1 Regulatory Filings	2024-04-18	English
Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2 Earnings Release FY 2024	2024-04-18	French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS Earnings Release FY 2023	2024-02-14	English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2023 ET FAIT UN POINT SUR SES ACTIVITÉS Earnings Release FY 2023	2024-02-14	French

Filings by year

2026 19 filings
2025 28 filings
2024 30 filings
2023 33 filings
2022 38 filings
2021 36 filings
2020 37 filings
2019 44 filings
2018 21 filings